Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
AIM: Nonadherence to glucagon-like peptide-1 receptor agonists (GLP1 RAs) is relatively common among patients with type 2 diabetes mellitus (T2DM). This study sought to identify reasons why patients discontinue GLP1 RAs. MATERIALS AND METHODS: Retrospective data from the Adelphi Diabetes Disease Specific Programme were used. Physicians managing patients with T2DM were surveyed via face-to-face interviews, and patients treated for T2DM were surveyed via self-completed questionnaires. Patient data were stratified by current versus prior GLP1 RA use. RESULTS: Physicians (n=443) most frequently reported inadequate blood glucose control (45.6%), nausea/vomiting (43.8%), and gastrointestinal (GI) side effects (36.8%) as reasons for GLP1 RA discontinuation. Patients (n=194) reported the GI-related issues "Made me feel sick" (64.4%) and "Made me throw up" (45.4%) as their top reasons for discontinuation. The most common problems reported (excluding cost) for those currently using GLP1 RAs were "Prefer oral medication over injections" (patients 56%, physicians 32.6%), "Made me feel sick" (patients 38.1%, physicians 16.3%), and "Did not help lose weight" (patients 25.4%, physicians 18%). The most bothersome problems for patients globally (frequency reporting very/extremely bothersome) (excluding cost) were "Difficult to plan meals around" (55.6%), "Made me throw up" (51.6%), and "Caused weight gain" (50%). CONCLUSION: Both patients and physicians reported GI-related issues as a prominent factor, but disparities between patient experiences and physician perceptions were revealed, suggesting gaps in physician-patient communication. Understanding patients' expectations of GLP1 RAs and physicians' patient-management practices may help increase GLP1 RA adherence and thereby potentially enhance diabetes care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For patients taking these medications for the treatment of obesity, there may be a particular reluctance to continue when weight loss plateaus or weight loss goals are reached”
From The societal implications of using glucagon-like peptide-1 receptor agonists for the treatment of obesity (2025) · cites this paper as [75]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Cost has consistently been cited as one of the most common barriers toward initiating and continuing GLP1-RA treatment, though there are still limited data on GLP1-RAs used solely for weight management.75,97,106”
From The societal implications of using glucagon-like peptide-1 receptor agonists for the treatment of obesity (2025) · cites this paper as [75]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the largest cross-sectional survey of GLP-1 RA discontinuation in routine practice to date, both physicians and patients converged on GI symptoms as a leading cause of treatment cessation, although the relative emphasis differed [54].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [54]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Surveyed physicians (n = 443) most frequently cited inadequate glycemic control (45.6%), nausea or vomiting (43.8%), and other GI side effects (36.8%) as reasons for stopping therapy in their patients; surveyed patients in turn most frequently cited nausea (64.4%) and vomiting (45.4%) as their principal reasons for abandoning treatment.”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [54]
In the citing paper
“In clinical practice, GI AEs (most commonly nausea) are known to be a common reason for discontinuation of GLP‐1RA treatment. 41”
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970 · cited 1×
“AEs with GLP1 RAs to be GI events, including diarrhea, nausea, and vomiting.(25) Given time, these common AEs usually subside.”
Anderson, P., Benford, M., Harris, N., Karavali, M., & Piercy, J. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802457040 · Cited by 522 · cited 2×
“A full description of the methodology has been published previously.(7)”
Self-citationA clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
Prasad-Reddy, L., & Isaacs, D. (2015) · Drugs in Context · doi:10.7573/dic.212283 · Cited by 365 · cited 1×
“For example, in clinical trials, <5% of patients discontinued a GLP1 RA due to GI effects; however, higher rates, between 5% and 10%, have been observed in clinical practice.(23,24) Clinical trials have reported the most common Figure 2 Reasons for GLP1 RA discontinuation in the past 6 months, ranked by frequency.”
GLP-1 receptor agonists: a review of head-to-head clinical studies
Trujillo, J. M., Nuffer, W., & Ellis, S. L. (2015) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814559725 · Cited by 282 · cited 1×
“Although clinical trials have demonstrated that GLP1 RAs are effective at reducing HbA 1c levels, these trials have also highlighted the differences in the type, frequency, and severity of adverse events (AEs) compared to insulin and among drugs within the GLP1 RA class.(20,21) Our results suggest the outcomes of thes…”
Higgins, V., Piercy, J., Roughley, A., Milligan, G., Leith, A., Siddall, J., & Benford, M. (2016) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s120101 · Cited by 260
Self-citationBabineaux, S. M., Curtis, B., Holbrook, T., Milligan, G., & Piercy, J. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-010352 · Cited by 253 · cited 1×
“Data used for this analysis are more likely to provide a representative, real-world sample of patients with T2DM and real-world patient behavior than randomized clinical trial data.(10,22) For example, in clinical trials, <5% of patients discontinued a GLP1 RA due to GI effects; however, higher rates, between 5% and 1…”
Self-citation7. Approaches to Glycemic Treatment
American Diabetes Association (2016) · Diabetes Care · doi:10.2337/dc16-s010 · Cited by 225
Seufert, J., & Gallwitz, B. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12251 · Cited by 156 · cited 1×
“16–19 This study suggests that this is the case for GLP1 RA users, as we found GI issues were three of the top five reasons for GLP1 RA discontinuation for patients across both geographic regions, indicating that patients may place more importance on factors that interrupt daily routines and…”
Elliott, L., Fidler, C., Ditchfield, A., & Stissing, T. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0157-z · Cited by 135 · cited 1×
“Data used for this analysis are more likely to provide a representative, real-world sample of patients with T2DM and real-world patient behavior than randomized clinical trial data.(10,22) For example, in clinical trials, <5% of patients discontinued a GLP1 RA due to GI effects; however, higher rates, between 5% and 1…”
Saunders, C., Byrne, C. D., Guthrie, B., Lindsay, R. S., McKnight, J. A., Philip, S., Sattar, N., Walker, J. J., Wild, S. H., & on behalf of the Scottish Diabetes Research Network Epidemiology Group (2013) · Diabetic Medicine · doi:10.1111/dme.12047 · Cited by 122 · cited 1×
“Additionally, up to 90% of patients with T2DM screened did not qualify for trials, and 49% of patients with newly diagnosed T2DM were found to be ineligible.(26) This finding underscores the importance of obtaining and using real-world data when possible, while remaining cautious when applying clinical trial findings…”
Cited by
Items 101–200 of 234
Cohen, C. M., Chodick, G., Husemoen, L. L. N., Rhee, N. A., Shalev, V., & Karasik, A. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0583-9 · Cited by 13
Pharmacotherapy for Obesity: Recent Updates
Fredrick, T. W., Camilleri, M., & Acosta, A. J. (2025) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s497904 · Cited by 33
Murugadoss, K., Varma, G., Venkatakrishnan, A., Gibson, M. C., & Soundararajan, V. (2026) · Biology Methods and Protocols · doi:10.1093/biomethods/bpag020 · Cited by 11
“There are various cited reasons for discontinuation, including gastrointestinal adverse effects, lack of treatment effect, out-of-pocket costs, and supply chain shortages [9–11].”
Singh, A. K., Singh, R., & Misra, A. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102436 · Cited by 13
Scheen, A. J. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2279193 · Cited by 13
“A real-world cross-sectional survey showed that both T2DM patients and physicians reported gastrointestinal adverse events as a prominent factor for poor adherence to GLP-1RAs and early discontinuation [62].”
BackgroundCurbing the Obesity Epidemic: Should GLP-1 Receptor Agonists Be the Standard of Care for Obesity?
Kaplan, J. M., Zaman, A., & Abushamat, L. A. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02097-4 · Cited by 12
“The most common side effects of GLP-1 RAs include nausea and vomiting due to delayed gastric emptying, thus these medications cannot be used in people with severe gastroparesis [66].”
Discovery of Selenium-Containing Derivatives as Potent and Orally Bioavailable GLP-1R Agonists
Chen, X., Xu, S., Yang, S. C., Yu, Z.-Z., Chen, Y., Wu, H., Bao, Q., You, Q., Guo, X., & Jiang, Z. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02616 · Cited by 11
Krishnanda, S. I., Christabelle, M., Yausep, O. E., Sugiharto, C., Vincent, L. D., Agarwal, R., Damara, I., & Harbuwono, D. S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14072239 · Cited by 10
“However, the traditional use of semaglutide via the subcutaneous route is not without challenges, particularly the issue of non-adherence [10,11].”
Yılmaz, N., & Baştemir, M. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s584175 · Cited by 15
Waataja, J. J., Asp, A. J., & Billington, C. J. (2023) · Biomedicines · doi:10.3390/biomedicines11092452 · Cited by 11
“However, as observed with many T2DM medications, adherence is a major problem with GLP-1 RAs with reported discontinuation in real-world scenarios to be approximately 45% at 1 year [28,29] due to unwanted side effects [30], high cost [31], and unwillingness to follow the physician’s treatment advice [32].”
BackgroundRiehl-Tonn, V. J., Medak, K. D., Rampersad, C., MacPhee, A., & Harrison, T. G. (2024) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581241290317 · Cited by 12
“106 However, once-weekly injectable GLP-1RA, semaglutide, increased medication adherence over other injectable administration schedules.”
BackgroundNausea and the Brain: The Chemoreceptor Trigger Zone Enters the Molecular Age
Han, W., & de Araújo, I. E. (2021) · Neuron · doi:10.1016/j.neuron.2021.01.004 · Cited by 10
Krishnan, A., Suryanarayanan, S., & Mansi, I. A. (2024) · Journal of Pharmacy Technology · doi:10.1177/87551225241266773 · Cited by 9
“28 Given these contrasting factors, this study aims to examine the utilization of these agents in the Veterans Health Administration (VHA) system, where prescribing these medications is relatively governed by formulary availability and prescribing policy.”
GLP-1 Receptor Agonists and Research to Treat Overeating and Substance Use Disorders
Guo, J. S., Hayes, M. R., Leggio, L., Oru, E., & Rinaman, L. (2025) · Journal of Neuroscience · doi:10.1523/jneurosci.1375-25.2025 · Cited by 13
Guo, X., Yang, W., Zhang, J., Dong, X., Liu, M. R., Gu, S., Lauand, F., Li, L., Huang, Q., Kang, L., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15074 · Cited by 9
Cheng, Z., Wang, S., Li, F., Jin, C., Mo, C., Zheng, J., Li, X., Liang, F., Yang, J.-K., & Gu, D. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.70013 · Cited by 12
Optimized suction patch design for enhanced transbuccal macromolecular drug delivery
Cerrejon, D. K., Krupke, H., Gao, D., Paunović, N., Sachs, D., & Leroux, J. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.02.014 · Cited by 10
European Guideline on Chronic Nausea and Vomiting—A UEG and ESNM Consensus for Clinical Management
Malagelada, C., Keller, J., Sifrim, D., Serra, J., Tack, J., Mulak, A., Stengel, A., Aguilar, A., Drewes, A. M., Josefsson, A., et al. (2025) · United European Gastroenterology Journal · doi:10.1002/ueg2.12711 · Cited by 8
Xie, Y., Choi, T., & Al-Aly, Z. (2026) · BMJ Medicine · doi:10.1136/bmjmed-2025-002150 · Cited by 8
“24 29 Discontinuation of GLP-1RAs is associated with weight regain and partial or complete reversal of some of the improvements in cardiometabolic risks (eg, blood glucose levels, blood pressure, lipid profile, and inflammatory markers).”
Voils, C. I., Gavin, K. L., Thorpe, C. T., Pabich, S., Reeve, B. B., Mian, G. J., Faacks, A., & Kronish, I. M. (2022) · Patient Preference and Adherence · doi:10.2147/ppa.s382885 · Cited by 8
NPYR modulation: Potential for the next major advance in obesity and type 2 diabetes management?
Lafferty, R. A., Flatt, P. R., & Irwin, N. (2024) · Peptides · doi:10.1016/j.peptides.2024.171256 · Cited by 9
“%) as the leading reason for discontinuation, followed by a preference for oral medications and inadequate glycaemic control (39.7 % and 34.5 %, respectively) [72].”
InfluentialPYY3-36 infused systemically or directly into the VTA attenuates fentanyl seeking in male rats
Caffrey, A., Lavecchia, E., Merkel, R., Zhang, Y., Chichura, K. S., Hayes, M. R., Doyle, R. P., & Schmidt, H. D. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109686 · Cited by 8
Sims, T. J., Boye, K. S., Robinson, S. J., & Kennedy‐Martin, T. (2022) · Patient Preference and Adherence · doi:10.2147/ppa.s367046 · Cited by 12
“The impact of hypoglycemia on indicators of initiation was evaluated in two studies,(15,25) on adherence indicators in four,(16,18,21,26) and on discontinuation in three.(23,24,26) Table 3 provides a summary of the main findings from these studies.”
BackgroundMethodResultInfluentialSex differences in GLP-1 signaling across speciesPreprint
Roseberry, T., Grossrubatscher, I., Krausz, T., Wang, Y.-J., Schwartz, M. W., & Tingley, D. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.17.643822 · Cited by 8
“Yet side effects of these drugs–particularly nausea and vomiting–are common in both clinical trials 9 and real world data 10 .”
Caffrey, A., Lavecchia, E., Chichura, K. S., Hayes, M. R., Doyle, R. P., & Schmidt, H. D. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70096 · Cited by 7
“While these results are promising from a translational perspective, caution is warranted due to the ability of GLP-1R agonists to induce nausea and emesis in humans, effects that limit patient compliance (Bettge et al., 2017; Sikirica et al., 2017).”
GLP1-RA and SGLT2-i: Implementation and Insulin Deescalation Strategies
Palani, A., Patel, S., Patel, S., Srivastava, S., Patel, J., Salehin, S., Birnbaum, Y., & Allencherril, J. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07744-8 · Cited by 8
“The ACCORD trial found that intensive glucose-lowering therapies were associated with increased all-cause mortality in patients with a history of cardiovascular disease, underscoring the importance of cautious titration [40].”
An, I. B., Byun, M. S., Yang, S. I., Choi, Y., Woo, J. W., Jang, H. C., & Sung, Y. C. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14058 · Cited by 7
“patients reported these symptoms as the most bothersome GLP-1RArelated problems.(8) In a retrospective analysis, 53.”
BackgroundKattaru, S., Mudhu, S. M., Samundeshwari, E. L., Sireesha, K., & Sarma, P. V. G. K. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06467-x · Cited by 7
Holmes‐Truscott, E., Schipp, J., Dunning, T. L., Furler, J., Hagger, V. L., Holloway, E. E., Manski-Nankervis, J.-A. E., Shaw, J. E., Skinner, T. C., & Speight, J. (2021) · Diabetic Medicine · doi:10.1111/dme.14681 · Cited by 7
Characterisation of real‐world patients who discontinued a glucagon‐like peptide‐1 agonist
Laren, J. V., Friesleben, C. R., Gershovich, O. E., Helm, L. A., Patel, R. J., & Delate, T. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70579 · Cited by 7
“28,29 Notably, mood changes were reported very infrequently (1 patient) as a reason for GLP-1 discontinuation in our patient sample.”
InfluentialPampanelli, S., Terzoni, S., Pantanetti, P., Loreto, C. D., Mazzieri, A., Cangelosi, G., Alberti, S., Badiali, C., Grandone, I., Migliarelli, S., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70538 · Cited by 8
Winkler, G., Hajós, P., & Kis, J. T. (2019) · Orvosi Hetilap · doi:10.1556/650.2019.31615 · Cited by 8
Snitker, S., Andersen, A., Berg, B., van Marle, S., & Sparre, T. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14349 · Cited by 5
“However, it was not reported whether there were differences between the drugs in this regard.(4) Received: 6 November 2020 Revised: 27 January 2021 Accepted: 9 February 2021”
BackgroundInfluentialYu, M., Yang, Z., Chen, C., Lv, Y., Xiang, L., Zhao, S., & Li, R. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00924-8 · Cited by 7
“[16, 17] GLP-1RAs would cause a loss of appetite and a significant improvement in body weight [18].”
BackgroundBailey, T. S., Gill, J., Merwyn Jones, S., Shenoy, L., Nicholls, C. J., & Westerbacka, J. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14739 · Cited by 7
“Despite clear evidence of the efficacy of GLP-1RAs, some patients do not experience lasting glycaemic control and require treatment intensification.(8,9) For PWD2 with suboptimal glycaemic control during oral antidiabetic drug or GLP-1RA therapy, the ADA and EASD recommend that sulphonylureas or insulin therapy should…”
BackgroundTakahashi, Y., Morimoto, T., Iekushi, K., & Arai, H. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64848 · Cited by 5
“The reasons for discontinuing glucagon-like peptide-1 receptor agonists were explored in a real-world cross-sectional survey of physicians and patients with type 2 diabetes 39) .”
A novel gene therapy platform for the treatment of type 2 diabetes and obesity
Lourie, J., Goraltchouk, A., Hollander, J. M., BERGER, N. J. A., Rosen, H. G., Fujishiro, A. A., Luppino, F., Seregin, A., Rhym, L. H., & Zou, K. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102739 · Cited by 6
“47 Discontinuation is driven primarily by pharmacokinetic spike-mediated GI side effects, as well as the high treatment cost and repeat injection burden, 48–50 which are major barriers to the global accessibility of GLP1 therapy.”
Ji, L., Gao, L., Tian, J., DONG, R., Zhang, Z., Shu, H., Zhao, J., Zhao, L., He, A., Xie, T., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02586-8 · Cited by 6
“18 These fi ndings indicate that there is an unmet need for effective weight-loss therapies with less frequent dosing frequency (e.g., biweekly or monthly), which may enhance treatment adherence and persistence and thereby ensure the delivery of the long-term bene fi ts associated with sustained…”
Edvardsson, C. E., Zhang, X., Emous, T. A., Adermark, L., Witley, S., Ericson, M., Schmidt, H. D., & Jerlhag, E. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106219 · Cited by 7
“Given GLP-1R agonists can produce nausea and emesis in drug-naïve rodents and humans 50,51 we measured kaolin clay consumption as an indicator of pica behaviour, the consumption of non-nutritive substances in response to emetic agents.”
Dunn, T. J., Zhu, Y., Gronroos, N. N., Xie, L., Sargent, A., Gamble, C. L., & Billings, L. K. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112162 · Cited by 5
EndoCompass project: research roadmap for diabetes, obesity, and metabolism
Mathieu, C., Meireles, M., Pagotto, U., Wabitsch, M., Banerjee, I., Bartolomé, A., Battelino, T., Beck, J., Chiarelli, F., León, D. D. D., et al. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf065 · Cited by 5
Treatment approaches for alcohol use disorder with metabolic dysfunction
Wagner, A. C., Jung, J., Pacher, P., & Lohoff, F. W. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108957 · Cited by 6
O’Connor, R. M. (2026) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2026.1805953 · Cited by 6
Cohen, C. M., Mosenzon, O., Aharonovich, A., Karasik, A., & Schechter, M. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112086 · Cited by 4
Bromocriptine and Colesevelam Hydrochloride: Novel Therapies for Type II Diabetes Mellitus
Soileau, L. G., Nguyen, A., Senthil, A., Boullion, J. A., Talbot, N. C., Ahmadzadeh, S., Shekoohi, S., Kaye, A. D., & Varrassi, G. (2023) · Cureus · doi:10.7759/cureus.50138 · Cited by 5
“While GI complaints were noted as a primary concern among both parties, the lack of blood glucose control and weight loss were other factors not effectively communicated, which potentially led to decreased adherence [25].”
BackgroundDziewierz, A., & Siudak, Z. (2026) · Nutrients · doi:10.3390/nu18111761 · Cited by 3
“In the largest cross-sectional survey of GLP-1 RA discontinuation in routine practice to date, both physicians and patients converged on GI symptoms as a leading cause of treatment cessation, although the relative emphasis differed [54].”
Jamal, A., Khan, S., Qadri, M., Shah, A., Iftikhar, H., Fatima, E., Ahmad, M., Sikandar, M., Jawed, I., Muneeb, M., et al. (2026) · Acta Diabetologica · doi:10.1007/s00592-025-02635-8 · Cited by 3
Malas, K., Kazmi, S., Kang, Y. M., & McGuire, D. K. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2504702 · Cited by 4
Pharmacological management of sleep apnea and obesity, a new frontier
Taweesedt, P. T., Orakpo, N., & Pelayo, R. (2025) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.11798 · Cited by 3
“16,17 Moreover, availability and accessibility are limited due to the high cost of medications, which are not cost-effective at their current net price.”
Is weight cycling clinically harmful?
Magkos, F., & Stefan, N. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00037-9 · Cited by 4
Heisey, H. D., Gregg, L. P., Verrico, C. D., Villareal, D. T., & Fletcher, T. L. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70913 · Cited by 4
Golembiewski, E. H., Ning, X., Mickelson, M. M., Gockerman, J. P., Tesulov, M., Labatte, B., & McCoy, R. G. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09509-3 · Cited by 3
“10,21 Interestingly, weight-related outcomes were not mentioned as significant in medication decisions among our participants, possibly because interviews were conducted in early 2022, before the widespread popularization of antihy-perglycemic medications that also promote weight loss (e.g.,…”
Zhang, Y., Zhao, Z., Kim, S. S.-E., Fabricatore, A. N., & Iyer, P. S. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2535464 · Cited by 4
“Real-world barriers such as high medication costs, insurance coverage limitations, and concerns about long-term safety and tolerability constrain the use of these therapies 33,34 .”
RoyChaudhuri, S., Majumder, A., Mukherjee, P., Sanyal, D., Chakraborty, S., & Chuyan, S. (2023) · Cureus · doi:10.7759/cureus.40179 · Cited by 4
“However, they failed to receive global acceptance as a result of clinical inertia due to three primary reasons: (a) cost of therapy, (b) injectable mode of administration, and (c) GI side effects [7].”
BackgroundRoyChaudhuri, S., Majumder, A., Sanyal, D., Chakraborty, S., & Chuyan, S. (2023) · Cureus · doi:10.7759/cureus.37065 · Cited by 5
“In a large US-based survey, gastrointestinal (GI) side effects and the injectable route of administration appear to be the prime hurdles for GLP1RAs initiation and the prime reason for their premature discontinuation [13].”
BackgroundQureshy, K., Kirk, A. R., Wolden, M. L., Zonoozi, A. A. M., & Liu, A. (2022) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000260 · Cited by 2
Qin, Y., Zhang, W., Zhang, H., Li, Y., Huang, W.-Q., Xie, J., Yang, S., Li, L., Cui, C., Pei, Q., et al. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2500303 · Cited by 2
“A cross-sectional survey [15] revealed that nausea and vomiting were the main reasons for treatment discontinuation, cited by 43.8% of physicians and 45.4–64.4% of patients.”
InfluentialGeisler, C. E., Chichura, K. S., Orativskyi, O., Hu, J., Belser, D. L., Pelletier, C. M., Borner, T., Baumer-Harrison, C., Jonghe, B. C. D., Crist, R. C., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adu6764 · Cited by 3
Bowe, A., Hayes, M., John, I., Diaz, M., Dixon, S. W., & Poonawalla, I. B. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70219 · Cited by 2
“GLP-1 RA-specific factors may contribute to this difference, including gastrointestinal side effects, 51 – 53 inadequate glucose control, 51,54 high out of pocket medication costs, 52,55 inability to obtain prescription fills and refills, 56 and dissatisfaction with any type of injection 51 or…”
Incorporating estimands into meta-analyses of clinical trials
Remiro‐Azócar, A., Polavieja, P., Boutmy, E., Ghiretti, A., Husemoen, L. L. N., Rantell, K. R., Vaitsiakhovich, T., Phillippo, D., Park, J., Lynggaard, H., et al. (2026) · Research Synthesis Methods · doi:10.1017/rsm.2026.10107 · Cited by 2
“…event strategies, e.g., if a relevant intercurrent event strategy is reported in some trials but not in others, multivariate (network) meta-analyses could be used to borrow information from trials in which the relevant estimands are reported, thereby accounting for the totality of evidence.”
A single-center retrospective study of GLP-1 agonist use in patients with hidradenitis suppurativa
Alkhalili, S., Hailemichael, R., Allen, C., Martin, S. A., Blaszczak, A. M., Flood, K. S., & Riley, J. M. (2025) · Archives of Dermatological Research · doi:10.1007/s00403-025-04443-0 · Cited by 2
Factors contributing to non-persistence of glucagon-like peptide-1 agonists: a cross-sectional study
Liu, S., Wong, G., Mavi, P., Gysel, S. C., Burton, D., Monteiro, N., Durocher, D., Sharma, A. M., & Tsuyuki, R. T. (2025) · Obesity Medicine · doi:10.1016/j.obmed.2025.100674 · Cited by 4
Sanger, G. J., Golding, J. F., & Andrews, P. L. R. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2682294 · Cited by 2
“Patients invariably consider nausea to be more serious than vomiting (e.g. CINV [115]), ranking it as of greater concern than health-care professionals [116].”
Nathani, P., Hamamah, S., Velji-Ibrahim, J., Patel, H. K., Nathani, R., Radadiya, D. K., Shandilya, A., Srinivasan, S., Desai, M., Repici, A., et al. (2026) · Digestive Diseases and Sciences · doi:10.1007/s10620-026-10112-7 · Cited by 3
“GI-AEs remain the most common reason for patients to discontinue treatment [21] .”
Khamnueva, L. Y., & Андреева, Л. С. (2023) · Problems of Endocrinology · doi:10.14341/probl13245 · Cited by 3
Renda, S., & Freeman, J. S. (2024) · Postgraduate Medicine · doi:10.1080/00325481.2024.2328511 · Cited by 2
“[15].”
Kruger, D. F., Isaacs, D. M., Hughes, L., Miller, E. M., & Bailey, T. S. (2024) · Postgraduate Medicine · doi:10.1080/00325481.2024.2331417 · Cited by 2
“Some PwD may not be willing to tolerate the side effects (e.g. gastrointestinal) [20], whereas others may not be able to afford these medications due to coverage issues or socioeconomic status.”
BackgroundAlshadfan, H., Mirghani, H. O., Alrasheed, T., Ibrahim, Y., Aljohani, S., Alanzi, T. S., Alshehri, S., Nurdin, A., & Abdullah, M. N. H. (2024) · Cureus · doi:10.7759/cureus.69805 · Cited by 2
“Importantly, patients with needle phobia and some physicians could avoid multiple injections [21].”
BackgroundModern-Day Management of the Dysglycemic Continuum: An Expert Viewpoint from the Arabian Gulf
Alessa, T., Alawadi, F., Alkaabi, J., Al-Mamari, A., Al‐Ozairi, E., Alromaihi, D., Elhadd, T. A., Gunaid, A. A., Hassanein, M. M., Jayyousi, A., et al. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s491591 · Cited by 3
Lu, D., Zheng, R., Li, A., & Zhang, J. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v16.i2.98552 · Cited by 3
Chau, H. C., Liu, J. Y. H., & Rudd, J. A. (2025) · Scientific Reports · doi:10.1038/s41598-025-95961-4 · Cited by 2
Mi, L., Li, T., Xiang, X., Zhou, Y., Xiong, N., Chen, Y., Chen, J., Shang, S., Chen, S., Cheung, W. W., et al. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.09.009 · Cited by 2
Bossi, A. C., Mori, V. D., Scaranna, C., Veronesi, G., Lepore, G., the ANDREW study group, Barbara, A., Rosalia, B., Antonio, B., Berzi, D., et al. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00929-4 · Cited by 2
Darbà, J., & Ascanio, M. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1859468 · Cited by 2
Golembiewski, E. H., Bautista, A. E. G., Polley, E. C., Umpierrez, G. E., Galindo, R. J., Brito, J. P., Montori, V. M., Gockerman, J. P., Tesulov, M., Labatte, B., et al. (2024) · Clinical Diabetes · doi:10.2337/cd23-0042 · Cited by 2
Yang, W., Guo, X., Lauand, F., Li, L., Fang, H., Du, Q., & Kang, L. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15414 · Cited by 1
“13,14 iGlarLixi, the fixed-ratio combination of BI glargine 100 units/ml (iGlar) and the short-acting GLP-1 RA lixisenatide (Lixi), is a titratable, once-daily option for individuals requiring intensification of T2D treatment that is approved in more than 70 countries, including China, 15 Japan, 16…”
BackgroundSashi, Rani, K., Rani, K., Ankita, A., Mittal, V., Kaushik, D. K., Dhall, M., Bamrah, P. K., Kumar, T., Pandey, M., et al. (2024) · Current Drug Therapy · doi:10.2174/0115748855276929231218053337 · Cited by 1
Refaeli, R., Green, G., Boaz, M., Dotan, I., Raziel, A., Peffer-Gik, T., Buch, A., & Dagan, S. S. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01887-2 · Cited by 2
“Clinical trials indicate that GI side effects lead to treatment discontinuation in fewer than 5 – 10% of patients [4 – 6, 8, 9, 22]; however, these rates are likely to be higher in clinical practice [21, 23 – 25].”
Rothberg, A. E., Ye, W., Miller, N., & Rizza, R. A. (2025) · Obesity Science & Practice · doi:10.1002/osp4.70092 · Cited by 1
Glucagon-like Peptide-1 Agonists and Exercise for Weight Reduction: A Review of Current Evidence
Owaidat, J. F., Zuaiter, S., Daseh, A. I., Nemrawi, F. A. A., Abu‐Jeyyab, M., & Al-Jafari, M. (2025) · JAP Academy Journal · doi:10.4103/japaj.japaj_5_24 · Cited by 1
Seighali, N., Chahkand, M. S. G., Ebrahimzade, M., Arashlow, F. T., Maroufi, S. P., Rahnama, P., Matin, M. H., Javazm, A. K., Ebrahimi, P., Nasir, K., et al. (2026) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-026-01149-5 · Cited by 2
“It can be used alongside dietary modification and physical activity by amplifying both weight loss and cardio-metabolic improvements with accessibility, better adherence, and patient preference compared to injectable form [14, 15].”
Neural Gastric Electrical Stimulation: Future Prospects in Managing Gastric Emptying Disorders
Sivakumar, J., Furness, J. B., Grayden, D. B., Fallon, J. B., Cottrell, J. J., & Duong, C. P. (2026) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm25106 · Cited by 1
Luca, S. A., Bungau, R. M., Herascu, A., Albai, A., Lazăr, S., & Timar, B. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15041674 · Cited by 1
“Drug-related side effects, like gastrointestinal events with incretin-based medications [29], may also contribute to the modest uptake of these agents observed in our cohort.”
Yang, S.-I., Kim, S. W., Son, K., Lee, S., Kim, J.-G., Roh, J.-I., & Sung, Y. C. (2026) · Nature Communications · doi:10.1038/s41467-026-71080-0 · Cited by 1
“HbA1c 7.0%), and treatment discontinuation remains a major challenge, driven largely by gastrointestinal side effects and inadequate glycemiccontrol,with~50%ofpatientsdiscontinuingtherapywithin12 months of initiation 2 – 4 .”
InfluentialStupalkowska, W., Henney, A. E., Riley, D. R. J., Sheu, E. G., Alam, U., & Cuthbertson, D. J. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70757 · Cited by 1
Gao, S., & Borner, T. (2026) · Appetite · doi:10.1016/j.appet.2026.108723 · Cited by 2
Piguet, C. E. M., Nucci, R., & Beaudry, J. L. (2026) · The Journal of Physiology · doi:10.1113/jp291081 · Cited by 1
Waataja, J. J., Ikramuddin, S., Gal, D., & Billington, C. J. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1002713 · Cited by 1
Cheng, F., Niu, X., Wang, Y., Yang, F., Yang, K., & Li, W. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01744-2 · Cited by 1
“Nevertheless, despite the benefits offered by GLP-1R agonist therapeutics, a significant number of patients do not meet their glycemic and weight loss objectives [11].”
Guan, H., Jiang, H., Yuan, H., Sun, J., Xu, J., & Ji, L. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70047 · Cited by 3
The benefit of GLP-1RA in different age groups in the cardiovascular outcome trials
Younes, A. M., Mishriky, B. M., Powell, J. R., & Cummings, D. M. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108878
Lingvay, I., Garvey, W. T., & Wadden, T. A. (2021) · JAMA · doi:10.1001/jama.2021.13024 · Cited by 1
Assessment of cardiovascular effects of non-insulin blood-glucose-lowering agents
Comoglio, N. H. (2019) · theses.fr (ABES) · doi:10.70675/5005dc38zdb1cz426cz8401z845e901eb81b
Danuglipron – an innovate GLP agonist - literature short review
Frańczuk, A., Szpulak, A., Kopczyńska, E., Makłowicz, A., Kuleta, K., Głoskowska, J., Grzelka, M., Słychan, K., Głuszczyk, A., & Plizga, J. I. (2024) · Quality in Sport · doi:10.12775/qs.2024.19.53802
Fujishiro, M., Nosoko, M., Ikeda, J., Takeuchi, M., Yamamotoya, T., Takayama, T., Urakami, T., Ogawa, K., & Ishihara, H. (2024) · Diabetology International · doi:10.1007/s13340-024-00758-x
“On the other hand, gastrointestinal side effects reportedly account for approximately half of the discontinuations due to adverse events associated with GLP-1 RA treatment [8].”
Yeremian, S., Keshishian, A., & Mardirosian, R. (2026) · PLoS ONE · doi:10.1371/journal.pone.0344917
Alhamedi, N. M. (2025) · Journal of Clinical Medical Research · doi:10.46889/jcmr.2025.6104 · Cited by 1
“…of GLP-1 Receptor Agonists (GLP-1RAs) among patients with type 2 diabetes mellitus, while excluding cost as a factor, it was found that gastrointestinal symptoms, specifically vomiting and nausea were the predominant reasons for discontinuation reported by both patients and physicians [24].”
McGuigan, A. (2025) · Drugs & Therapy Perspectives · doi:10.1007/s40267-025-01154-4
Antiemetic effect of acupressure wristbands for GLP-1 medication associated nausea
Ziemke, F., Belarj, S., Esguerra, J., Reyes, A., & Istfan, N. W. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100178
“The effect of GLP-1a on gastrointestinal (GI) function, namely delaying of gastric emptying and intestinal motility, additionally contribute to the occurrence of GI side effects as a whole [9,39,40].”
Goode, R. W., Harper-Cooks, T., Campos, A. P., Matthes, K. E., Robles, J., Calderon, C. M., Lee, M., Robinson, M. N., & Alexander, R. (2025) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2025.08.001
Metadata
- Authors
- Sikirica, M., Martin, A., Wood, R., Leith, A., Piercy, J., & Higgins, V.
- Affiliations
- GlaxoSmithKline (United States) (US)
- GlaxoSmithKline (United Kingdom) (GB)
- Adelphi Group (United Kingdom) (GB)
- Corresponding author
- Sikirica, Mirko
- Venue
- Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2017-09
- Volume
- Volume 10
- Pages
- 403-412
- ISSN
- 1178-7007 (ISSN-L)
- PMC
- PMC5630073
- OpenAlex
- W2763255780
- Cited by
- 223
- References
- 21
- Citations by year
- 2026: 40 · 2025: 54 · 2024: 34 · 2023: 23 · 2022: 21 · 2021: 22 · 2020: 13 · 2019: 11 · 2018: 5
- FWCI
- 6.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Diabetes Metabolic Syndrome and Obesity (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- GlaxoSmithKline
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, drug discontinuation, medication adherence, gastrointestinal adverse effects, nausea and vomiting, physician-patient communication, patient expectations, weight gain, physician perceptions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.